ClinicalTrials.gg

Rhinitis, Allergic, Seasonal clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 404 studies for Rhinitis, Allergic, Seasonal across more than 10 countries. 24 are recruiting or about to start. 349 of them are mainly about Rhinitis, Allergic, Seasonal (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.

Status

Completed
348
Recruiting
17
Status unknown
14
Terminated
10
Not yet recruiting
6
Withdrawn
4

Phase

Phase 3
130
Phase 2
112
Phase 4
53
Phase 1
42
Early Phase 1
3

Where

United States
107
Germany
41
Canada
33
China
27
United Kingdom
19
Austria
17

Who develops what

Add Rhinitis, Allergic, Seasonal to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 13 companies, 15 with this as their studies’ main aim; 6 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Sino Biopharmaceutical, Akeso and AO GENERIUM here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
rupatadine fumarateRecent, limited
Evidence
  • NCT07711262 · Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Rupatadine Fumarate Tablets” · registered Jul 2026
J. Uriach and Company100% of its industry studies11 study
FluticasoneEarlier only
Evidence
  • NCT03882047 · Organon & Co. · Phase 3 · comparator · “Fluticasone propionate” · registered Mar 2019
  • NCT03599791 · Viatris Inc. · Phase 3 · comparator · “Fluticasone Propionate 0.05 MG/ACTUAT” · registered Jul 2018
  • NCT03004131 · Viatris Inc. · Phase 4 · comparator · “fluticasone propionate nasal spray + loratadine” · registered Dec 2016
  • NCT02246920 · Teva Pharmaceutical Industries, Ltd. · Phase 3 · comparator · “Flonase®” · registered Sep 2014
  • NCT01260753 · Palau Pharma S.L.U. · Phase 2 · comparator · “Fluticasone propionate nasal spray” · registered Dec 2010
GlaxoSmithKline35% of its industry studiesUS: off-patent, 25 generics marketed00 studies
LoratadineEarlier only
Evidence
  • NCT03004131 · Viatris Inc. · Phase 4 · comparator · “fluticasone propionate nasal spray + loratadine” · registered Dec 2016
  • NCT02932774 · Johnson & Johnson · Phase 4 · comparator · “Loratadine” · registered Sep 2016
  • NCT02478398 · Merck & Co., Inc · Phase 3 · background · “Loratadine” · registered Jun 2015
  • NCT01413958 · Bayer · Phase 3 · background · “Loratadine” · registered Aug 2011
  • NCT01330017 · Bayer · Phase 2 · background · “Loratadine” · registered Apr 2011
Bayer23% of its industry studiesUS: off-patent, 32 generics marketed00 studies

8 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
drotokibart☆ Track1 live phase-3 study: NCT07688772Jiangsu HengRui Medicine Co., Ltd.
stapokibart☆ Track1 live phase-3 study: NCT07678931Chengdu Kangnuoxing Biopharma,Inc.
telikibart☆ Track2 live phase-3 studies: NCT07199257, NCT07154342Chongqing Genrix Biopharmaceutical Co., Ltd
Rupatifen Fumarate Capsules☆ Track1 live phase-3 study: NCT07711262Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.
LisinoprilApproved: US☆ Track1 live phase-3 study: NCT07291284Longbio Pharma

The 5 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.TQH2722 · Sino Biopharmaceutical Limited · Phase 2 main aimNCT07398859 Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis — primary endpoint: Number of subjects with incidence of adverse event · 300 enrolled
  • Dec 2026 est.drotokibart · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 main aimNCT07688772 A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis — primary endpoint: Mean change from baseline in the daily reflective Total Nasal Symptom Score (rTNSS) within 2 weeks of treatment. · 220 enrolled
  • Dec 2026 est.stapokibart · Chengdu Kangnuoxing Biopharma,Inc. · Phase 3 main aimNCT07678931 Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis — primary endpoint: Mean change from baseline in daily reflective total nasal symptom scores (rTNSS) over 2 weeks of treatment · 136 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Rhinitis, Allergic, Seasonal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antihistamines 70 · Corticosteroids 68

Coming up

10studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10, phase 3 first

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger. 1 (6%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (29%) take healthy volunteers.

Recruiting studies that take each age, of 17
AgeWomenMen
100 (0%)0 (0%)
1817 (100%)17 (100%)
3016 (94%)16 (94%)
4016 (94%)16 (94%)
5016 (94%)16 (94%)
6514 (82%)14 (82%)
757 (41%)7 (41%)
852 (12%)2 (12%)

Across all 404 studies, recruiting or not: 67% stop at 75 or younger and 60% at 65; 37% take children; <1% are for women only and 2% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Rhinitis, Allergic, Seasonal studies take

Of 37 phase 3 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 4 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 15 mo4–9 · 16 studies——
Phase 25 mo3–23 · 24 studies——
Phase 34 mo2–14 · 37 studies4 mo1–14 · 31 studies—
Interventional, no phase7 mo2–22 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 404. Browse all 404 → or search them.